- Home
- STT vs BNTX Comparison
STT vs BNTX Comparison
Compare STT & BNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | STT | BNTX |
|---|---|---|
| Founded | 1792 | 2008 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.3B | 24.8B |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | STT | BNTX |
|---|---|---|
| Price | $126.95 | $92.11 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 11 |
| Target Price | $127.92 | ★ $137.40 |
| AVG Volume (30 Days) | ★ 1.8M | 1.4M |
| Earning Date | 01-16-2026 | 11-03-2025 |
| Dividend Yield | ★ 2.64% | N/A |
| EPS Growth | ★ 49.61 | N/A |
| EPS | ★ 9.43 | N/A |
| Revenue | ★ $13,626,000,000.00 | $3,698,814,972.00 |
| Revenue This Year | $8.21 | $2.36 |
| Revenue Next Year | $4.53 | N/A |
| P/E Ratio | $13.48 | ★ N/A |
| Revenue Growth | ★ 8.59 | 3.70 |
| 52 Week Low | $72.81 | $81.20 |
| 52 Week High | $131.37 | $129.27 |
Technical Indicators
Market Signals| Indicator | STT | BNTX |
|---|---|---|
| Relative Strength Index (RSI) | 63.83 | 32.83 |
| Support Level | $126.49 | $91.40 |
| Resistance Level | $131.36 | $97.35 |
| Average True Range (ATR) | 2.67 | 2.28 |
| MACD | 0.55 | -0.40 |
| Stochastic Oscillator | 66.80 | 4.74 |
Price Performance
Historical ComparisonAbout STT State Street Corporation
State Street is a leading provider of financial services, including investment servicing, investment management, and investment research and trading. With approximately $49 trillion in assets under custody and administration, and $5.1 trillion in assets under management, as of June 30, 2025, State Street operates globally in more than 100 geographic markets and employs about 53,000 worldwide.
About BNTX BioNTech SE
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.